CN105661547A - Probiotics and Bombyx mori compounded diabetic patient nutritional supplement - Google Patents
Probiotics and Bombyx mori compounded diabetic patient nutritional supplement Download PDFInfo
- Publication number
- CN105661547A CN105661547A CN201610041973.9A CN201610041973A CN105661547A CN 105661547 A CN105661547 A CN 105661547A CN 201610041973 A CN201610041973 A CN 201610041973A CN 105661547 A CN105661547 A CN 105661547A
- Authority
- CN
- China
- Prior art keywords
- mulberry
- supplementary
- probiotics
- weight portions
- microcapsule
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000006041 probiotic Substances 0.000 title claims abstract description 52
- 235000018291 probiotics Nutrition 0.000 title claims abstract description 52
- 206010012601 diabetes mellitus Diseases 0.000 title claims abstract description 29
- 241000255789 Bombyx mori Species 0.000 title claims abstract description 25
- 235000015872 dietary supplement Nutrition 0.000 title abstract 4
- 239000003094 microcapsule Substances 0.000 claims abstract description 30
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 24
- 235000013325 dietary fiber Nutrition 0.000 claims abstract description 21
- 150000004676 glycans Chemical class 0.000 claims abstract description 21
- 229920001282 polysaccharide Polymers 0.000 claims abstract description 21
- 239000005017 polysaccharide Substances 0.000 claims abstract description 21
- 229940124277 aminobutyric acid Drugs 0.000 claims abstract description 20
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 claims abstract description 20
- 241000382353 Pupa Species 0.000 claims abstract description 18
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims abstract description 18
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims abstract description 18
- 239000011701 zinc Substances 0.000 claims abstract description 18
- 229910052725 zinc Inorganic materials 0.000 claims abstract description 18
- 240000000249 Morus alba Species 0.000 claims abstract description 16
- 235000008708 Morus alba Nutrition 0.000 claims abstract description 16
- 230000000529 probiotic effect Effects 0.000 claims description 44
- SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 claims description 40
- 241000894006 Bacteria Species 0.000 claims description 24
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 claims description 20
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 claims description 20
- 239000002131 composite material Substances 0.000 claims description 15
- 239000000203 mixture Substances 0.000 claims description 8
- 238000002360 preparation method Methods 0.000 claims description 8
- 238000009472 formulation Methods 0.000 claims description 6
- 239000002994 raw material Substances 0.000 claims description 6
- 241000186016 Bifidobacterium bifidum Species 0.000 claims description 5
- 238000007796 conventional method Methods 0.000 claims description 5
- 239000000843 powder Substances 0.000 claims description 5
- 238000000034 method Methods 0.000 claims description 4
- 230000008569 process Effects 0.000 claims description 3
- 210000004369 blood Anatomy 0.000 abstract description 15
- 239000008280 blood Substances 0.000 abstract description 15
- 230000000694 effects Effects 0.000 abstract description 11
- 231100000331 toxic Toxicity 0.000 abstract description 7
- 230000002588 toxic effect Effects 0.000 abstract description 7
- 102000004196 processed proteins & peptides Human genes 0.000 abstract description 6
- 229920001184 polypeptide Polymers 0.000 abstract description 5
- 150000001413 amino acids Chemical class 0.000 abstract description 3
- 230000003247 decreasing effect Effects 0.000 abstract description 2
- 108090000623 proteins and genes Proteins 0.000 abstract description 2
- 102000004169 proteins and genes Human genes 0.000 abstract description 2
- 239000013543 active substance Substances 0.000 abstract 1
- HEBKCHPVOIAQTA-NGQZWQHPSA-N d-xylitol Chemical compound OC[C@H](O)C(O)[C@H](O)CO HEBKCHPVOIAQTA-NGQZWQHPSA-N 0.000 abstract 1
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 20
- 102000004877 Insulin Human genes 0.000 description 10
- 108090001061 Insulin Proteins 0.000 description 10
- 229940125396 insulin Drugs 0.000 description 10
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 7
- 239000008103 glucose Substances 0.000 description 7
- 230000000968 intestinal effect Effects 0.000 description 7
- 239000003814 drug Substances 0.000 description 6
- 235000013305 food Nutrition 0.000 description 6
- 208000024172 Cardiovascular disease Diseases 0.000 description 4
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 230000002708 enhancing effect Effects 0.000 description 3
- 230000002218 hypoglycaemic effect Effects 0.000 description 3
- 230000036039 immunity Effects 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 238000007873 sieving Methods 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 229920002527 Glycogen Polymers 0.000 description 2
- 206010020772 Hypertension Diseases 0.000 description 2
- 206010023379 Ketoacidosis Diseases 0.000 description 2
- 208000007976 Ketosis Diseases 0.000 description 2
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 2
- 229960004373 acetylcholine Drugs 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 238000009395 breeding Methods 0.000 description 2
- 230000001488 breeding effect Effects 0.000 description 2
- 230000023852 carbohydrate metabolic process Effects 0.000 description 2
- 235000021256 carbohydrate metabolism Nutrition 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 2
- 229940096919 glycogen Drugs 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 230000002440 hepatic effect Effects 0.000 description 2
- 230000003345 hyperglycaemic effect Effects 0.000 description 2
- 230000003914 insulin secretion Effects 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 2
- HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical compound C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 description 1
- BOVGTQGAOIONJV-BETUJISGSA-N 1-[(3ar,6as)-3,3a,4,5,6,6a-hexahydro-1h-cyclopenta[c]pyrrol-2-yl]-3-(4-methylphenyl)sulfonylurea Chemical compound C1=CC(C)=CC=C1S(=O)(=O)NC(=O)NN1C[C@H]2CCC[C@H]2C1 BOVGTQGAOIONJV-BETUJISGSA-N 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 241000186000 Bifidobacterium Species 0.000 description 1
- 229940123208 Biguanide Drugs 0.000 description 1
- 108010075254 C-Peptide Proteins 0.000 description 1
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 1
- 208000002249 Diabetes Complications Diseases 0.000 description 1
- 206010012655 Diabetic complications Diseases 0.000 description 1
- 208000032928 Dyslipidaemia Diseases 0.000 description 1
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- 206010020710 Hyperphagia Diseases 0.000 description 1
- 208000013016 Hypoglycemia Diseases 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- 240000001046 Lactobacillus acidophilus Species 0.000 description 1
- 235000013956 Lactobacillus acidophilus Nutrition 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 208000017170 Lipid metabolism disease Diseases 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 206010027336 Menstruation delayed Diseases 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 229940100389 Sulfonylurea Drugs 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 150000004283 biguanides Chemical class 0.000 description 1
- 239000003613 bile acid Substances 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 230000004531 blood pressure lowering effect Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 229910001424 calcium ion Inorganic materials 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 229940099352 cholate Drugs 0.000 description 1
- BHQCQFFYRZLCQQ-OELDTZBJSA-N cholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 BHQCQFFYRZLCQQ-OELDTZBJSA-N 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 229960000346 gliclazide Drugs 0.000 description 1
- 201000001421 hyperglycemia Diseases 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 239000002955 immunomodulating agent Substances 0.000 description 1
- 230000002584 immunomodulator Effects 0.000 description 1
- 229940121354 immunomodulator Drugs 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 239000012567 medical material Substances 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- DUWWHGPELOTTOE-UHFFFAOYSA-N n-(5-chloro-2,4-dimethoxyphenyl)-3-oxobutanamide Chemical compound COC1=CC(OC)=C(NC(=O)CC(C)=O)C=C1Cl DUWWHGPELOTTOE-UHFFFAOYSA-N 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 235000008935 nutritious Nutrition 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000000505 pernicious effect Effects 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- 206010036067 polydipsia Diseases 0.000 description 1
- 208000022530 polyphagia Diseases 0.000 description 1
- 230000000291 postprandial effect Effects 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 210000001525 retina Anatomy 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 210000002955 secretory cell Anatomy 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- YROXIXLRRCOBKF-UHFFFAOYSA-N sulfonylurea Chemical class OC(=N)N=S(=O)=O YROXIXLRRCOBKF-UHFFFAOYSA-N 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 238000011282 treatment Methods 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/51—Bifidobacterium
Landscapes
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
The invention discloses a probiotics and Bombyx mori compounded diabetic patient nutritional supplement.The probiotics and Bombyx mori compounded diabetic patient nutritional supplement is prepared from, by weight, 90-110 CFU of activated probiotics micro-capsules, 3-8 parts of aminobutyric acid, 9-12 parts of xylooligosaccharide, 1-5 parts of zinc-rich yeast, 2-6 parts of mulberry polysaccharide, 1-3 parts of silkworm pupa protein peptide and 10-24 parts of dietary fibers.Multiple activated probiotics are matched with short peptides, amino acids, the water-soluble dietary fibers and the like reasonably, growth and reproduction of intra-intestinal probiotics are promoted by the activated probiotics, and silkworm pupa polypeptides cooperate with biologically active substances such as active polysaccharides to decrease blood sugar.Compared with the prior art, the probiotics and Bombyx mori compounded diabetic patient nutritional supplement has the advantages of capability of decreasing blood sugar effectively, convenience in eating, little toxic or side effect and the like.
Description
Technical field
The invention belongs to nutritious health caring food technology field, be specifically related to diabetes patient's supplementary of the composite silkworm and mulberry of a kind of probiotic bacteria.
Background technology
Diabetes are the general names of a series of metabolic disturbance, and internal amount of insulin can be caused to reduce for it or insulin utilizes insufficient, thus causing hyperglycemia. Adding up according to World Health Organization (WHO), the current whole world has more than 100,000,000 3 thousand ten thousand people to suffer from diabetes, and diabetes have become as No. three killer in the whole world, are only second to cardiovascular and cerebrovascular disease. The course of disease of diabetes is long, if mistake is controlled, wrong treatment, then the chronic complication of blood vessel, kidney, retina and nervous system very easily occurs, and patient is very harmful, brings great misery to vast diabetics. Usual diabetes patient is divided into type i diabetes and type ii diabetes, wherein type i diabetes age of onset is light, mostly < 30 years old, onset is unexpected, and polydipsia polyuria polyphagia symptom of becoming thin is obvious, blood sugar level is high, many patients with ketoacidosis for onset symptoms, serum insulin and C peptide low SI, ICA, IAA or GAD antibody can be positive, alone oral medicine is invalid, need to treat with insulin. Type ii diabetes is common in middle-aged and elderly people, and overweight people's sickness rate is high, often can with hypertension, the disease such as dyslipidemia, arteriosclerosis. Insidious onset, early stage is without any symptom, or only has slightly weak, thirsty, and blood glucose increases inconspicuous person need to be done carbohydrate tolerance test and just can make a definite diagnosis. Serum insulin levels early stage is normal or increases, and late period is low.
Diabetes are that a kind of chronic metabolic is sick, and the medicine treating diabetes at present has chemical drugs (such as sulfonylurea, gliclazide, biguanides etc.), insulin, Chinese medicine three major types. But the route of administration major part of chemical drugs is oral, has action time short, toxic action is big, the feature that dependency is strong. If diabetes do not obtain strong control, hypoglycemia, ketoacidosis can be caused.Although the allotment of normal meals is conducive to balanced nutrients to control blood glucose, but will according to patient's physical condition, prepare food for special foods targetedly, supplement appropriate high-quality protein and the several functions factor, strengthen resistance against diseases, more can effectively auxiliary hyperglycemic with prevent life-threatening complication from occurring.
Are planted medical material by 4 kinds of probiotic bacterias and more than 50 for Chinese invention patent CN103404757B and various food is mixed in proportion and obtains the special diet edible for hyperglycemic patients, though this technical scheme product has high joint blood sugar for human body, reduce the effect of diabetic complication, but its formula is excessively complicated, and after needing high-temperature maturing when making, decocting can be taken, and brings inconvenience to user.
Summary of the invention
For the defect of prior art, present invention aim at providing diabetes patient's supplementary of the composite silkworm and mulberry of a kind of probiotic bacteria, it has can effectively reduce the advantages such as blood glucose, instant, toxic and side effects be little.
The present invention is achieved through the following technical solutions:
Diabetes patient's supplementary of the composite silkworm and mulberry of a kind of probiotic bacteria, is made up of following raw material: active probiotic microcapsule, aminobutyric acid, oligomeric xylose, yeast rich in zinc, polysaccharides of Folium Mori, pupa albumen peptide and dietary fiber; Wherein said active probiotic microcapsule is 90～11,000,000,000 CFU; Described aminobutyric acid is 3～8 weight portions; Described oligomeric xylose is 9～12 weight portions, and described yeast rich in zinc is 1～5 weight portion, and described polysaccharides of Folium Mori is 2～6 weight portions, and described pupa albumen peptide is 1～3 weight portion; Described dietary fiber is 10～24 weight portions.
Preferably, described active probiotic microcapsule is bacillus bifidus microcapsule.
Preferably, described oligomeric xylose is 2:3 with the weight ratio of described dietary fiber.
Preferably, described aminobutyric acid is 5:3 with the weight ratio of described yeast rich in zinc.
Preferably, described polysaccharides of Folium Mori is 5:2 with the weight ratio of described pupa albumen peptide.
Further, described active probiotic microcapsule adopts double-layer embedment microcapsule process to prepare.
Preferably, described active probiotic microcapsule is 10,000,000,000 CFU, and described aminobutyric acid is 5 weight portions, described oligomeric xylose is 10 weight portions, and described yeast rich in zinc is 3 weight portions, and described polysaccharides of Folium Mori is 5 weight portions, described pupa albumen peptide is 2 weight portions, and described dietary fiber is 15 weight portions.
Preferably, described active probiotic microcapsule is 10,000,000,000 CFU, and described aminobutyric acid is 500mg, described oligomeric xylose is 1000mg, and described yeast rich in zinc is 300mg, and described polysaccharides of Folium Mori is 500mg, described pupa albumen peptide is 200mg, and described dietary fiber is 1500mg.
Further, product of the present invention is agitated uniformly sieve after adopt conventional method make granular preparation or powder formulation.
The lipoteichoic acid contained in described active probiotic microcapsule especially bacillus bifidus microcapsule is a kind of important immunomodulator, has infection, antitumor, blood fat reducing and delays the biological actions such as diabetes generation. The damage of Pancreas Islet Structure and function is had protective effect by bacillus acidophilus.
Described yeast rich in zinc has enhancing insulin active, controls blood glucose, regulates fat stores amount, reduces Blood Cholesterol and content of triglyceride, prevents cardiovascular diseases.
Described oligomeric xylose is by the selective proliferative to probiotic bacterias such as bacillus bifiduss, probiotic bacteria is made to be in the ascendance in intestinal microbial population, in addition bifidobacterium fermentation oligomeric xylose, the acidic materials such as acetic acid, propanoic acid can be produced, improve medicine absorption environment in intestinal, strengthen other components assimilation effect in intestinal.
Described aminobutyric acid can increase the generation of acetylcholine, and acetylcholine directly facilitates the secretion of insulin after acting on m receptor.Described aminobutyric acid can protect insulin secretory cell from infringement, can reduce again the body immune system immunoreation to this kind of cell simultaneously. Additionally, described aminobutyric acid can also stop the progress even reversing type i diabetes.
Described polysaccharides of Folium Mori can promote β cells secrete insulin, and then promotes that cell to the utilization of sugar, hepatic glycogen synthesis and improves carbohydrate metabolism, is finally reached hypoglycemic effect.
Described dietary fiber can delay the absorption of the carbohydrate in food on the one hand, makes post-prandial glycemia ascensional range reduce, and glucose in urine output reduces; On the other hand, dietary fiber can be combined with bile acid at enteral, increases cholate and discharges from feces, therefore has the effect reducing blood cholesterol, and this is to preventing and treating what the most concurrent cardiovascular diseases of diabetes was also advantageous that.
Described silkworm chrysalis polypeptide contains arginine, lysine, leucine and phenylalanine etc. insulin secretion is had stronger stimulation. Except having good blood sugar decreasing effect, also there is good blood pressure lowering effect simultaneously.
The present invention is by various active probiotic bacteria and the reasonably collocation such as small peptide (silkworm chrysalis polypeptide), aminoacid and water soluble dietary fiber; the growth and breeding of enteral probiotic bacteria is promoted by active probiotic; suppress the growth of putrefaction bacteria; form one protective barrier at intestinal mucosal surface simultaneously; and by promote beneficial bacteria of intestinal tract growth and breeding can also enhancing human body immunity power, the collaborative blood sugar lowering of bioactive substance such as silkworm chrysalis polypeptide and active polysaccharide (polysaccharides of Folium Mori).
Compared with prior art, the method have the advantages that
1, active permanent, stomach juice-resistant. Adopt the active probiotic microcapsule prepared of double-layer embedment microcapsule process, such active probiotic microcapsule have permanent activity, stomach juice-resistant, can effectively field planting intestinal, people source bacterial strain.
2, blood glucose is effectively reduced. The various ingredients synergism such as silkworm chrysalis polypeptide and oligomeric xylose, stimulates insulin secretion on the one hand, promotes that cell to the utilization of sugar, hepatic glycogen synthesis and improves carbohydrate metabolism on the other hand.
3, instant, toxic and side effects is little. The food composition that each composition is all direct-edible, toxic and side effects is little; And active probiotic and the oligomeric xylose in formula is respectively provided with the propagation suppressing pernicious bacteria, it is not necessary to additionally add preservative and can realize storage-stable, reduce the toxic and side effects caused because of additive; User does not need additionally to adjust diet, can realize good hypoglycemic effect.
4, immunity, complication prevention are increased. In inventive formulation, contained active probiotic microcapsule can effectively safeguard intestinal normal bacteria colony balance, suppress the growth of pathogen, prevent gastrointestinal disorders etc., synthetic vitamin, aminoacid and the absorption to calcium ion of the raising body in intestinal, strengthen human immunologic function, prevent antibiotic side effect, enhancing human body immunity power, the complication such as prophylaxis of hypertension or cardiovascular diseases.
Detailed description of the invention
Below in conjunction with specific embodiment, the present invention will be further described.
Diabetes patient's supplementary of the composite silkworm and mulberry of a kind of probiotic bacteria, is made up of following raw material: active probiotic microcapsule, aminobutyric acid, oligomeric xylose, yeast rich in zinc, polysaccharides of Folium Mori, pupa albumen peptide and dietary fiber; Wherein said active probiotic microcapsule is 90～11,000,000,000 CFU; Described aminobutyric acid is 3～8 weight portions; Described oligomeric xylose is 9～12 weight portions, and described yeast rich in zinc is 1～5 weight portion, and described polysaccharides of Folium Mori is 2～6 weight portions, and described pupa albumen peptide is 1～3 weight portion;Described dietary fiber is 10～24 weight portions.
Described active probiotic microcapsule is bacillus bifidus microcapsule, and the weight ratio of described oligomeric xylose and described dietary fiber is 2:3, and the weight ratio of described aminobutyric acid and described yeast rich in zinc is 5:3, and the weight ratio of described polysaccharides of Folium Mori and described pupa albumen peptide is 5:2.
Embodiment 1:
Formula: active probiotic microcapsule: 10,000,000,000 CFU
Aminobutyric acid: 500mg
Oligomeric xylose: 1000mg
Yeast rich in zinc: 300mg
Polysaccharides of Folium Mori: 500mg
Pupa albumen peptide: 200mg
Dietary fiber: 1500mg
Preparation: above-mentioned raw materials mixing is mixed thoroughly and adopts conventional method to make granular preparation or powder formulation after sieving.
Embodiment 2:
Formula: active probiotic microcapsule: 11,000,000,000 CFU
Aminobutyric acid: 300mg
Oligomeric xylose: 1200mg
Yeast rich in zinc: 180mg
Polysaccharides of Folium Mori: 360mg
Pupa albumen peptide: 144mg
Dietary fiber: 1800mg
Preparation: above-mentioned raw materials mixing is mixed thoroughly and adopts conventional method to make granular preparation or powder formulation after sieving.
Embodiment 3:
Formula: active probiotic microcapsule: 9,000,000,000 CFU
Aminobutyric acid: 800mg
Oligomeric xylose: 900mg
Yeast rich in zinc: 480mg
Polysaccharides of Folium Mori: 250mg
Pupa albumen peptide: 100mg
Dietary fiber: 1350mg
Preparation: above-mentioned raw materials mixing is mixed thoroughly and adopts conventional method to make granular preparation or powder formulation after sieving.
Compared with prior art, product of the present invention has and can effectively reduce the advantages such as blood glucose, instant, toxic and side effects be little.
It is above the present invention has been carried out exemplary description; the realization of the obvious present invention is not subject to the restrictions described above; as long as have employed the various improvement that technical solution of the present invention carries out; or the not improved design by the present invention and technical scheme directly apply to other occasion, all in protection scope of the present invention.
Claims (9)
1. diabetes patient's supplementary of the composite silkworm and mulberry of probiotic bacteria, it is characterised in that be made up of following raw material: active probiotic microcapsule, aminobutyric acid, oligomeric xylose, yeast rich in zinc, polysaccharides of Folium Mori, pupa albumen peptide and dietary fiber; Wherein said active probiotic microcapsule is 90～11,000,000,000 CFU; Described aminobutyric acid is 3～8 weight portions; Described oligomeric xylose is 9～12 weight portions, and described yeast rich in zinc is 1～5 weight portion, and described polysaccharides of Folium Mori is 2～6 weight portions, and described pupa albumen peptide is 1～3 weight portion; Described dietary fiber is 10～24 weight portions.
2. diabetes patient's supplementary of composite silkworm and mulberry of probiotic bacteria according to claim 1, it is characterised in that: described active probiotic microcapsule is bacillus bifidus microcapsule.
3. diabetes patient's supplementary of composite silkworm and mulberry of probiotic bacteria according to claim 1, it is characterised in that: the weight ratio of described oligomeric xylose and described dietary fiber is 2:3.
4. diabetes patient's supplementary of composite silkworm and mulberry of probiotic bacteria according to claim 1, it is characterised in that: the weight ratio of described aminobutyric acid and described yeast rich in zinc is 5:3.
5. diabetes patient's supplementary of composite silkworm and mulberry of probiotic bacteria according to claim 1, it is characterised in that: the weight ratio of described polysaccharides of Folium Mori and described pupa albumen peptide is 5:2.
6. diabetes patient's supplementary of composite silkworm and mulberry of probiotic bacteria according to claim 1, it is characterised in that: described active probiotic microcapsule adopts double-layer embedment microcapsule process to prepare.
7. diabetes patient's supplementary of composite silkworm and mulberry of probiotic bacteria according to claim 1, it is characterized in that: described active probiotic microcapsule is 10,000,000,000 CFU, described aminobutyric acid is 5 weight portions, described oligomeric xylose is 10 weight portions, described yeast rich in zinc is 3 weight portions, described polysaccharides of Folium Mori is 5 weight portions, and described pupa albumen peptide is 2 weight portions, and described dietary fiber is 15 weight portions.
8. diabetes patient's supplementary of composite silkworm and mulberry of probiotic bacteria according to claim 1, it is characterized in that: described active probiotic microcapsule is 10,000,000,000 CFU, described aminobutyric acid is 500mg, described oligomeric xylose is 1000mg, described yeast rich in zinc is 300mg, described polysaccharides of Folium Mori is 500mg, and described pupa albumen peptide is 200mg, and described dietary fiber is 1500mg.
9. diabetes patient's supplementary of the composite silkworm and mulberry of probiotic bacteria according to any one of claim 1～8, it is characterised in that: diabetes patient's supplementary of the composite silkworm and mulberry of described probiotic bacteria is agitated uniformly sieve after adopt conventional method make granular preparation or powder formulation.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610041973.9A CN105661547A (en) | 2016-01-22 | 2016-01-22 | Probiotics and Bombyx mori compounded diabetic patient nutritional supplement |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610041973.9A CN105661547A (en) | 2016-01-22 | 2016-01-22 | Probiotics and Bombyx mori compounded diabetic patient nutritional supplement |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN105661547A true CN105661547A (en) | 2016-06-15 |
Family
ID=56302077
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610041973.9A Pending CN105661547A (en) | 2016-01-22 | 2016-01-22 | Probiotics and Bombyx mori compounded diabetic patient nutritional supplement |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105661547A (en) |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107307417A (en) * | 2017-06-17 | 2017-11-03 | 深圳市领治医学科技有限公司 | A kind of type 2 diabetes patient's nutriment |
| CN107495362A (en) * | 2017-08-02 | 2017-12-22 | 深圳市领治医学科技有限公司 | A kind of Diabetic Nephropathy patients nutriment |
| CN107981343A (en) * | 2017-12-20 | 2018-05-04 | 佳木斯大学附属第医院 | Nutritional preparation of diabetic patients and preparation method thereof |
| CN113559150A (en) * | 2021-06-23 | 2021-10-29 | 广西康康康生物科技发展集团有限公司 | Preparation method and application of silkworm chrysalis-mulberry juice composite fermentation preparation |
| CN113969297A (en) * | 2021-10-30 | 2022-01-25 | 福州三合元生物科技有限公司 | Oligomeric gamma-aminobutyric acid and preparation method thereof |
Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1351085A (en) * | 2001-11-27 | 2002-05-29 | 广东省农业科学院蚕业研究所 | Mulberry leaf polyose and its usage |
| CN102415523A (en) * | 2010-09-26 | 2012-04-18 | 保龄宝生物股份有限公司 | Composition containing compound functional food factor |
| CN102960600A (en) * | 2012-11-19 | 2013-03-13 | 陕西科技大学 | Method for preparing two-layer embedded bifidobacterium microcapsules |
| CN103619343A (en) * | 2010-12-07 | 2014-03-05 | 高等科学研究委员会 | Bifidobacterium cect 7765 and use thereof in the prevention and/or treatment of excess weight, obesity and related pathologies |
| CN104031963A (en) * | 2014-04-02 | 2014-09-10 | 浙江省农业科学院 | Method for preparing hpyerglycemic peptide by using silkworm chrysalis |
| CN104187682A (en) * | 2014-09-25 | 2014-12-10 | 青岛嘉瑞生物技术有限公司 | Preparation technology for blood-sugar-reducing health Chinese herbal gluten peptides |
| CN105039217A (en) * | 2015-07-16 | 2015-11-11 | 山东凤凰生物有限公司 | Hypoglycemic probiotic preparation and its preparation method |
-
2016
- 2016-01-22 CN CN201610041973.9A patent/CN105661547A/en active Pending
Patent Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1351085A (en) * | 2001-11-27 | 2002-05-29 | 广东省农业科学院蚕业研究所 | Mulberry leaf polyose and its usage |
| CN102415523A (en) * | 2010-09-26 | 2012-04-18 | 保龄宝生物股份有限公司 | Composition containing compound functional food factor |
| CN103619343A (en) * | 2010-12-07 | 2014-03-05 | 高等科学研究委员会 | Bifidobacterium cect 7765 and use thereof in the prevention and/or treatment of excess weight, obesity and related pathologies |
| CN102960600A (en) * | 2012-11-19 | 2013-03-13 | 陕西科技大学 | Method for preparing two-layer embedded bifidobacterium microcapsules |
| CN104031963A (en) * | 2014-04-02 | 2014-09-10 | 浙江省农业科学院 | Method for preparing hpyerglycemic peptide by using silkworm chrysalis |
| CN104187682A (en) * | 2014-09-25 | 2014-12-10 | 青岛嘉瑞生物技术有限公司 | Preparation technology for blood-sugar-reducing health Chinese herbal gluten peptides |
| CN105039217A (en) * | 2015-07-16 | 2015-11-11 | 山东凤凰生物有限公司 | Hypoglycemic probiotic preparation and its preparation method |
Non-Patent Citations (2)
| Title |
|---|
| 周吉银等: "糖尿病的发病机理与γ-氨基丁酸的作用", 《中国临床药理学与治疗学》 * |
| 朱寅荣等: "双歧杆菌与2型糖尿病的关系", 《医学综述》 * |
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107307417A (en) * | 2017-06-17 | 2017-11-03 | 深圳市领治医学科技有限公司 | A kind of type 2 diabetes patient's nutriment |
| CN107495362A (en) * | 2017-08-02 | 2017-12-22 | 深圳市领治医学科技有限公司 | A kind of Diabetic Nephropathy patients nutriment |
| CN107981343A (en) * | 2017-12-20 | 2018-05-04 | 佳木斯大学附属第医院 | Nutritional preparation of diabetic patients and preparation method thereof |
| CN113559150A (en) * | 2021-06-23 | 2021-10-29 | 广西康康康生物科技发展集团有限公司 | Preparation method and application of silkworm chrysalis-mulberry juice composite fermentation preparation |
| CN113559150B (en) * | 2021-06-23 | 2022-09-27 | 广西康康康生物科技发展集团有限公司 | Preparation method and application of silkworm chrysalis-mulberry juice composite fermentation preparation |
| CN113969297A (en) * | 2021-10-30 | 2022-01-25 | 福州三合元生物科技有限公司 | Oligomeric gamma-aminobutyric acid and preparation method thereof |
| CN113969297B (en) * | 2021-10-30 | 2024-03-26 | 福州三合元生物科技有限公司 | Oligomeric gamma-aminobutyric acid and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN106619743A (en) | Probiotic solid drink with hypoglycaemic effect and preparation method of probiotic solid drink | |
| CN108112996A (en) | A kind of alimentation composition for controlling diabetes B crowd hyperglycaemia and improving immunity | |
| CN106174585A (en) | Hypoglycemic compositions and hypoglycemic compound probiotic spy's dietary seafood | |
| CN105661547A (en) | Probiotics and Bombyx mori compounded diabetic patient nutritional supplement | |
| CN109221898A (en) | A kind of grain dust and its preparation method and application containing xylo-oligosaccharide | |
| CN104147132A (en) | Soft gel capable of reducing blood sugar and adjusting insulin secretion and production method | |
| CN110338402A (en) | A kind of compound probiotic powder and preparation method thereof | |
| CN106912960A (en) | A kind of hypoglycemia healthcare food and preparation method thereof | |
| CN104855985A (en) | Non-complete-nutrition formula food for high uric acid | |
| CN104855994A (en) | Non-full nutritional formula food for patients with nephropathy | |
| CN101564160B (en) | Food for preventing and treating hyperlipemia and hyperglycemia and preparation method thereof | |
| CN104855997A (en) | Non-whole nutrient formula food for osteoporosis | |
| JP4132635B2 (en) | Uninactivated enzyme-enhanced composition | |
| CN110710660A (en) | Blood sugar lowering composition and dietary supplement containing bitter gourd powder | |
| CN105707378A (en) | Black-highland barley coffee with effect of slimming | |
| CN108713755A (en) | Quinoa weight reducing nutrition milk shake | |
| CN110432500A (en) | A kind of prebiotic compositions and preparation method and purposes containing inulin | |
| CN105727253A (en) | Composition for protecting liver, clearing away toxic materials, preventing and treating liver and related metabolic diseases and preparation method thereof | |
| CN105475855B (en) | High microsteping mung bean protein peptide composite nutrient food and its Green production method | |
| CN103656624B (en) | A kind of compound silkworm pupa hypoglycemic health-care pharmaceutical composition and its preparation method and application | |
| CN107582845A (en) | A kind of Plant Powder for preventing and treating diabetes | |
| CN107095297A (en) | A kind of nutritional health food | |
| CN1958035A (en) | Composition of medication in use for reducing blood sugar, blood fat, and treating diabetes | |
| CN107259318A (en) | A kind of nutritional health food | |
| CN111264865A (en) | Thyroid nodule medical formula food and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20160615 |
|
| RJ01 | Rejection of invention patent application after publication |